What percentage of the cost of avatrombopag will be reimbursed by medical insurance?

Avatrombopag, trade name Sucoxin, is an oral thrombopoietic agent, mainly used to treat thrombocytopenia caused by chronic liver disease or chronic immune thrombocytopenia (ITP). At present, the drug has been officially launched in my country and has been successfully included in the national medical insurance directory, which will undoubtedly reduce the financial burden for the majority of patients. Being included in medical insurance means that some patients’ drug costs can be reimbursed through medical insurance. The specific proportion varies according to local medical insurance policies.

Generally speaking, avatrombopag is available in two specifications in China: 20mg10 tablets and 20mg15 tablets, which are priced at around 5,000 yuan and 7,000 to 8,000 yuan respectively. According to the current medical insurance policies of most provinces and cities, if the patient is eligible for medical insurance reimbursement (such as outpatient treatment for chronic diseases, hospitalization, etc.), the reimbursement ratio for drug expenses is mostly between 60%-80%, and in some areas it can even be reimbursed up to 90%. However, there are also restrictions such as deductibles, ceilings, and out-of-pocket ratios. Therefore, it is recommended that patients consult the local hospital pharmacy or medical insurance office to confirm their personal medical insurance benefits before seeking treatment.

It is worth noting that although the reimbursement ratio of domestic medical insurance is relatively high, the cost may still be heavy for some patients with financial difficulties or who do not meet the conditions for medical insurance. Therefore, many people will also consider purchasing generic drugs through overseas channels. At present, the Lao version and the Bangladeshi version of the generic version of avatrombopag have been officially launched on the market. The drug ingredients are consistent with the original drug and the price is more affordable. The price of each box is only a few hundred yuan, providing patients with a practical alternative under high economic pressure.

In summary, avatrombopag has been included in the medical insurance reimbursement system in China, which can reduce the drug cost burden for most patients. However, the specific reimbursement amount still needs to refer to local policies and personal medical insurance conditions. Patients should understand the medical insurance reimbursement process in advance before taking medicine, and weigh whether to choose domestic original drugs or overseas generic drugs based on their own financial situation and treatment needs to obtain a more cost-effective treatment plan. No matter which channel you choose, you should ensure that the source of drugs is regular, safe and reliable.

Reference materials:https://go.drugbank.com/drugs/DB11995